ZenOncoIO

Founded in 2019, ZenOncoIO operates in Health Tech industry.

In-Clinic HealthcareFunded

What ZenOncoIO does

Founded in 2019, ZenOncoIO operates in Health Tech industry. Originally aimed at offering a blend of conventional and complementary therapies to cancer patients, the company has expanded its services to include cancer-specific nutrition, emotional counselling, and access to specialists. ZenOncoIO has developed a care management platform to enhance patient access to personalised care plans and support throughout their treatment journey. It has broadened its offerings by integrating technology to provide online consultations and support networks for patients and caregivers. Competing with companies such as Onco and MOC.

No open roles recorded right now.

That does not mean they are not hiring — plenty of roles never reach a job board. The careers page below is the earliest place a new opening appears.

Who runs it

Dimple Parmar
Kishan Shah

Funding and finances

Total raised$1.4M
Last stageEarly Stage
Rounds1
Last raised2021-11-29
Revenue (FY31)25300000
Net margin-0.57
Investors
Apollo Hospitals EnterpriseArvind KumarBetter CapitalEnzia VenturesTitan Capital

Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.

Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.

Questions and experiences

Nobody has asked anything about ZenOncoIO yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.

Reviewed before it appears. Do not include anything that identifies you or anyone else.

Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.

jobo is a browser extension. Open this on a computer to install it.